The Role of Luspatercept in the Evolving Treatment Landscape of LR-MDS

Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes (LR-MDS), with a focus on achieving hemoglobin levels ≥ 10, as highlighted by Santini et al in their ASH 2024 abstract, demonstrating the clinical significance of this target for improving patient outcomes.